Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

CIBC World Keeps 'Buy' on Amgen


CIBC World reiterates buy on Amgen (AMGN).

Analyst Matt Geller says the completion of the company's Immunex acquisition is ahead of Amgen's second quarter earnings call on July 24, and will give the company an opportunity to report combined guidance.

Meanwhile, Geller says high volume Monday in Amgen's stock most likely involved arbitragers closing positions. He notes weakness may have involved the removal of Immunex from indices, which may have resulted in the sell-off.

Geller thinks Amgen's current share price takes into account much of the downside risk. However, for those unwilling to take risk, he suggests waiting until after the earnings call to buy the stock. Geller sees $1.43 2002 earnings per share.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus